IBB

Equity ETFs

Pharmaceutical ETFs Could Maintain Their Momentum

Pharmaceutical ETFs Could Maintain Their Momentum

By Max ChenSeptember 6, 2018

Equity ETFs

Healthcare ETFs Are Among Best Performing Defensive Picks This Year

7 Healthcare ETFs Among Best Performing Defensive Picks This Year

By Max ChenAugust 22, 2018

Equity ETFs

Biotech ETFs Rally as Illumina Tops Second Quarter Expectations

Biotech ETFs Rally as Illumina Tops Q2 Expectations

By Max ChenJuly 31, 2018

Equity ETFs

Biotech ETFs Climb on Biogen's Promising Clinical Trial

Biotech ETFs Climb on Biogen’s Promising Clinical Trial

By Max ChenJuly 6, 2018

Equity ETFs

Biotech ETFs Look Promising as White House May Help FDA Expedite Drug Approvals

Will “Right to Try” Bill Boost Biotech ETFs?

By Tom LydonMay 24, 2018

Equity ETFs

6 Top Healthcare ETFs Rally as Trump Vows End to 'Global Freeloading'

6 Top Healthcare ETFs Rally as Trump Vows End to ‘Global Freeloading’

By Max ChenMay 11, 2018

Equity ETFs

Healthcare ETFs Lag Markets as Celgene Drags

Healthcare ETFs Lag Markets as Celgene Drags

By Max ChenApril 30, 2018

Equity ETFs

Big Biotech ETF Can Bounce Back

Big Biotech ETF Can Bounce Back

By Tom LydonApril 18, 2018

Equity ETFs

Alkermes FDA Refusal Biotech ETFs Dragged Down

Alkermes FDA Refusal: Biotech ETFs Dragged Down

By Max ChenApril 2, 2018

Investing

Try This ETF Pair to Round Out Biotech Exposure

By David DierkingMarch 23, 2018

Equity ETFs

Good Reasons to Stick With Biotech ETFs

Good Reasons to Stick With Biotech ETFs

By Tom LydonMarch 12, 2018

Equity ETFs

Biotech ETFs Pop on Celgene, Juno Deal

Biotech ETFs Pop on Celgene, Juno Deal

By Max ChenJanuary 22, 2018

Equity ETFs

Biotech ETFs Can be Solid Again in 2018

Biotech ETFs Can be Solid Again in 2018

By Tom LydonDecember 20, 2017

Equity ETFs

Calls For Biotech ETF Rally Gain Steam

Biotech ETFs to be Tested by Technicals

By Brenton GarenDecember 8, 2017

Equity ETFs

Biotech Slump Could be a Buying Opportunity

Biotech Slump Could be a Buying Opportunity

By Tom LydonDecember 5, 2017

Equity ETFs

Biotech Decline Could be a Buying Opportunity

Biotech Decline Could be a Buying Opportunity

By Brenton GarenNovember 16, 2017

Equity ETFs

Biotech ETFs Struggle on Celgene Shock Waves

Biotech ETFs Struggle on Celgene Shock Waves

By Brenton GarenNovember 3, 2017

Equity ETFs

A Biotech Pullback Could be Afoot

A Biotech Pullback Could be Afoot

By Brenton GarenOctober 26, 2017

Previous 1 … 6 7 8 9 10 … 23 Next